We are live on
!
Find out more
NCM
Nantahala Capital Management Portfolio holdings
AUM
$2.72B
1-Year Est. Return
121.58%
This Fund
S&P 500
This Quarter
Est. Return
+11.08%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.03B
AUM Growth
-$271M
(-21%)
Cap. Flow
-$280M
Cap. Flow
% of AUM
-27.07%
Top 10 Holdings %
Top 10 Hldgs %
51.2%
Holding
145
New
21
Increased
20
Reduced
48
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Bancorp
TBBK
|
+$12.6M |
| 2 |
Cytokinetics
CYTK
|
+$5.52M |
| 3 |
Dyne Therapeutics
DYN
|
+$4.89M |
| 4 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$4.82M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$4.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TA
TravelCenters of America LLC
TA
|
+$51.7M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$45.4M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$24M |
| 4 |
Travel + Leisure Co
TNL
|
+$23.3M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$13.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.04% |
| 2 | Financials | 9.2% |
| 3 | Consumer Discretionary | 9.01% |
| 4 | Communication Services | 6.73% |
| 5 | Industrials | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AAN
76
DELISTED
The Aaron's Company Inc
AAN
| $1.96M | 0.19% |
138,572
-150,000
| -52% | -$1.85M |
|
77
Neuropace
NPCE
$507M
| $1.91M | 0.18% |
424,850
-1,075
| -0.3% | -$4.86K |
|
78
Spyre Therapeutics
SYRE
$9.29B
| $1.85M | 0.18% |
164,048
-18,272
| -10% | -$86.6K |
|
79
ADC Therapeutics
ADCT
$144M
| $1.81M | 0.17% |
840,000
| – | – |
|
80
AYTU BioPharma
AYTU
$25.5M
| $1.74M | 0.17% |
1,086,812
+815,217
| +300% | +$1.6M |
|
81
CALL
eHealth
EHTH
$40.4M
| $1.63M | 0.16% |
203,100
+54,500
| +37% | +$436K |
|
|
JBIO
82
Jade Biosciences
JBIO
$1.32B
| $1.63M | 0.16% |
2,714
| – | – |
|
83
Rezolute
RZLT
$451M
| $1.52M | 0.15% |
769,606
| – | – |
|
|
MACK
84
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $1.37M | 0.13% |
111,148
-80,118
| -42% | -$1M |
|
85
NN Inc
NNBR
$300M
| $1.26M | 0.12% |
+526,006
| New | +$797K |
|
86
ARS Pharmaceuticals
SPRY
$587M
| $1.21M | 0.12% |
+180,097
| New | +$1.2M |
|
|
ANEB
87
DELISTED
Anebulo Pharmaceuticals
ANEB
| $1.2M | 0.12% |
511,073
| – | – |
|
88
Cartesian Therapeutics
RNAC
$265M
| $1.12M | 0.11% |
33,333
| – | – |
|
|
ACER
89
DELISTED
Acer Therapeutics Inc
ACER
| $1.05M | 0.1% |
1,136,416
-66,710
| -6% | -$59.1K |
|
|
SGRP
90
DELISTED
SPAR Group
SGRP
| $955K | 0.09% |
758,032
+61,454
| +9% | +$74.1K |
|
|
91
Travel + Leisure Co
TNL
$4.5B
| $928K | 0.09% |
23,016
-605,463
| -96% | -$23.3M |
|
92
Elicio Therapeutics
ELTX
$81.4M
| $902K | 0.09% |
94,939
-3,335
| -3% | -$30.6K |
|
|
DHC
93
Diversified Healthcare Trust
DHC
$2.04B
| $890K | 0.09% |
395,613
-4,993,024
| -93% | -$7.17M |
|
94
SCYNEXIS
SCYX
$51.2M
| $885K | 0.09% |
37,500
| – | – |
|
95
Unicycive Therapeutics
UNCY
$138M
| $829K | 0.08% |
64,742
| – | – |
|
96
Taysha Gene Therapies
TSHA
$1.83B
| $827K | 0.08% |
1,251,139
-471,261
| -27% | -$341K |
|
97
Cogent Biosciences
COGT
$7.1B
| $759K | 0.07% |
+64,132
| New | +$736K |
|
|
BGRY
98
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $705K | 0.07% |
+500,000
| New | +$693K |
|
|
APTO
99
DELISTED
Aptose Biosciences, Inc.
APTO
| $679K | 0.07% |
4,874
-6,190
| -56% | -$1.28M |
|
100
Carvana
CVNA
$81.5B
| $648K | 0.06% |
+125,000
| New | +$347K |
|
Similar funds
TAM
XL
NB
PA
BCM
SCM
HCM
GC
Nantahala Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Nantahala Capital Management held 145 positions worth $1.03B, down 21% from $1.31B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Nantahala Capital Management withdrew a net $280M in Q2 2023, closing 21 positions and reducing 48 holdings. Its most notable exit was TravelCenters of America LLC, an estimated $51.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 38% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Nantahala Capital Management opened a new position in The Bancorp worth $13.3M.
- Nantahala Capital Management's largest Q2 2023 buy was The Bancorp: 407,946 shares worth $13.3M.
- Nantahala Capital Management added most to Cytokinetics in Q2 2023, an estimated $5.52M increase.
- Nantahala Capital Management's biggest Q2 2023 reduction was iShares Russell 2000 ETF, cutting an estimated $24M.
- Nantahala Capital Management fully exited TravelCenters of America LLC in Q2 2023, selling an estimated $51.7M.
- Nantahala Capital Management's ten largest holdings make up 51% of its $1.03B portfolio in Q2 2023.
- Nantahala Capital Management opened 21 new positions and closed 21 in Q2 2023.
- Nantahala Capital Management's portfolio value fell 21% quarter-over-quarter to $1.03B.
Based on Nantahala Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.